RxDoctor Payments Data

Ryan Brown, MD

Cardiovascular Disease · Walnut Creek, CANPI 1467425439

Payments from drug & device makers

$71,100in general payments, 2019–2025

Across 355 payments — averaging $200.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$63K
  • Shockwave Medical, Inc$1K
  • Boston Scientific$727
  • Edwards Lifesciences$680
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$612
  • Boehringer Ingelheim$439
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$8,361100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,100 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$716,843
Medicare patients
2,517
Services billed
7,664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban338$424,979
XareltoRivaroxaban139$164,593
EntrestoSacubitril/Valsartan63$65,082
BrilintaTicagrelor51$38,312
Repatha SureclickEvolocumab52$36,341
MultaqDronedarone Hcl26$35,271
Praluent PenAlirocumab28$27,501
JardianceEmpagliflozin14$21,071
Repatha PushtronexEvolocumab23$15,570
VascepaIcosapent Ethyl16$12,672
Rosuvastatin Calcium463$7,711
Clonidine18$6,497
Ezetimibe187$5,993
Ranolazine ErRanolazine30$5,527
Metoprolol Succinate313$5,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$424,979338 claims
Johnson & JohnsonXarelto$191$164,593139 claims
NovartisEntresto$309$65,08263 claims
AstraZenecaBrilinta$308$38,31251 claims
Sanofi-aventis U.S. LLCMultaq$35$35,27126 claims
Boehringer IngelheimJardiance$439$21,07114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →